#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroblastoma recurrent Endocrine ophthalmopathy B-cell type acute leukaemia Bile acid synthesis disorder Renal disorder Iron overload Eosinophilic oesophagitis Bronchiolitis Gastric cancer Primary adrenal insufficiency Raynaud's phenomenon Hypoxic-ischaemic encephalopathy Leukocyte adhesion deficiency Cerebral arteriovenous malformation haemorrhagic Cerebral amyloid angiopathy More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma – Treatment Congenital generalised lipodystrophy Activated PI3 kinase delta syndrome – Trials in Disease Adrenocortical carcinoma Cholangitis sclerosing – Trials in Disease Amyotrophic lateral sclerosis – Diagnostics Systemic mastocytosis – Diagnostics Prader-Willi syndrome – Treatment Malignant fibrous histiocytoma Retinoblastoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ursodeoxycholic Acid Corifollitropin Alfa Tetrahydrouridine Sodium S-Lactate Solution Giredestrant Quizartinib Dihydrochloride Ripretinib Ceftriaxone Sodium Ecopipam Hydrochloride Nimorazole Fedratinib Anhydrous Cholestyramine Vobramitamab Duocarmazine Tavapadon Gs-5245 Epirubicin Hydrochloride Nemolizumab RO7268489 Phleum Pratense Img-007 More therapies…

    Learn about Your Condition

    Blood disorder Arthritis infective Cardiogenic shock Colitis Chronic hepatitis C Epidermolysis bullosa Tubulointerstitial nephritis Mantle cell lymphoma stage II Thrombosis Mantle cell lymphoma stage III Metastases to lymph nodes Syphilis Carotid artery occlusion Rectosigmoid cancer Malignant melanoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Brentuximab Vedotin
    • Dexamethasone Phosphate
    • Dacarbazine
    Poland

  • Lidocaine Hydrochloride, Sodium Chloride, and Betamethasone Injections for Adults with Adhesive Capsulitis: A Pilot Efficacy Study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Periarthritis
    Investigated Drugs:
    • Betamethasone Dipropionate
    • Lidocaine Hydrochloride
    • Betamethasone Sodium Phosphate
    France

  • Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    • Ruxolitinib
    Austria Belgium Czechia France Germany Italy +3

  • Short‑course sublingual ITULAZAX birch pollen extract with Lactobacillus rhamnosus GG for patients with pollen‑associated food allergy

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • Betula Verrucosa (108)
    Germany

  • Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Daratumumab
    • Obinutuzumab
    • Venetoclax
    Poland

  • Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • T-cell type acute leukaemia
    Investigated Drugs:
    • Tofacitinib
    • Everolimus
    • Venetoclax
    Czechia France Germany The Netherlands Spain
Previous Page
1 … 703 704 705 706 707 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!